Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Combines Its Life Sciences and Diagnostics Businesses

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.

Agilent Technologies Inc. announces it has combined its Life Sciences Group with its Diagnostics and Genomics business, naming Lars Holmkvist the new group's president and senior vice president of Agilent, effective immediately. Holmkvist was previously president of the Diagnostics and Genomics Group and senior vice president of Agilent.

The split will see one company focused on life sciences, diagnostics and applied markets, retaining the Agilent name, and the other focused on electronic measurement, which will be named later.

Agilent, the life sciences, diagnostics and applied markets company, will be comprised of two businesses - the Chemical Analysis Group, led by Mike McMullen, current group president and Agilent senior vice president, and the new Life Sciences and Diagnostics Group, under Holmkvist as its president. Nick Roelofs, who has been president of the Life Sciences Group, will leave Agilent to pursue other business opportunities.

"We are creating a new Agilent with a simplified structure that can move quickly to develop and deliver industry-leading total workflow solutions for our customers," said William (Bill) Sullivan, Agilent president and CEO. "Lars is the ideal leader for the new group with his years of experience, depth of market knowledge and superb leadership style."

Agilent also announced that with the spinoff of its electronic measurement business, it has created a new Agilent Order Fulfillment organization. Henrik Ancher-Jensen has been named president of Agilent Order Fulfillment and senior vice president of Agilent. He replaces Gooi Soon Chai, who is joining the electronic measurement spinoff company. Ancher-Jensen was previously vice president, Global Product Supply, for Agilent's Diagnostics and Genomics Group, and corporate vice president, Global Operations, for Dako.

"Henrik understands the priority of customer satisfaction while at the same time contributing to margin expansion goals. His experience and drive for excellence makes him a great match for this important position," Sullivan said.

"The new simplified organization positions an already strong set of businesses for greater growth and shareholder return," Sullivan said.

Lars Holmkvist
Holmkvist joined Agilent in June 2012, when Agilent acquired Dako. He had been president and CEO of Dako since 2009. Before joining Dako, Holmkvist served as president, Europe, for Applied Biosystems, where he was later promoted to president, International, with responsibilities for all commercial operations outside the U.S.

Holmkvist brings more than 25 years' experience within the medical device and pharmaceutical industries, where he has held increasingly significant roles in marketing, sales and business management. He holds a degree in economics from Handelshogskolan Sundsvall in Sweden.

Henrik Ancher-Jensen
Ancher-Jensen came to Agilent in June 2012 with the acquisition of Dako. He joined Dako in 2006 as vice president, Supply Chain, and chief information officer, and was subsequently promoted to corporate vice president, Global Operations. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE. Ancher-Jensen holds a degree in economics from Aarhus University in Denmark.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Reports Third-Quarter Results
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.
Thursday, August 15, 2013
Agilent Technologies Reports Fourth-Quarter 2012 Results
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.
Tuesday, November 20, 2012
Scientific News
Molecule Prevents Effect of Chemotherapy
Danish researchers from Aarhus University Hospital and Aarhus University have made a possible breakthrough in the treatment of colorectal cancer.
Peptide Mutants Help Identify Vulnerability in Tumor Cells
Researchers can detect mutant proteins based on MS data and the results of exome sequencing.
Misfiring Drugs Hit the Wrong Targets
Anti-HIV protein inhibitor drugs can bind to the wrong protein, causing unwanted side effects.
New Possibilities Tumor Research
Grazer researchers say gene activity of the tumor from the analysis of circulating DNA in blood ahead.
Parkinson’s Test Could Aid Early Detection
A test that can detect Parkinson’s disease in the early stages of the illness has moved a step closer.
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Breakthrough in GPCR Understanding
Integral Molecular announces breakthrough in understanding the functionality of GPCRs, the largest class of drug targets in human disease.
Designing Ultrasound Tools with Lego-Like Proteins
Study outlines how ultrasound technology can be used for imaging in conjuction with protein engineering.
Enzyme that Triggers Cell Demise in ALS Identified
Scientists from Harvard have identified a key instigator of nerve cell damage in people with amyotrophic lateral sclerosis (ALS).
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!